ADAR1 Capital Management’s BridgeBio Pharma BBIO Stock Holding History

ADAR1 Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.2M	Buy	176,689 +82,397	+87%	+$5.77M	0.6%	41
2026 Q1	$7M	Sell	94,292 -119,122	-56%	-$8.63M	0.41%	59
2025 Q4	$16.3M	Sell	213,414 -60,000	-22%	-$3.94M	1.2%	17
2025 Q3	$14.2M	Buy	273,414 +13,755	+5%	+$671K	1.33%	14
2025 Q2	$11.2M	Sell	259,659 -79,976	-24%	-$2.91M	1.72%	13
2025 Q1	$11.7M	Sell	339,635 -339,222	-50%	-$11.4M	2.18%	10
2024 Q4	$18.6M	Sell	678,857 -769,613	-53%	-$19.9M	3.72%	7
2024 Q3	$36.9M	Buy	1,448,470 +183,900	+15%	+$4.83M	6%	3
2024 Q2	$32M	Buy	1,264,570 +714,766	+130%	+$19.5M	6.05%	5
2024 Q1	$17M	Buy	549,804 +364,667	+197%	+$12.4M	3.86%	10
2023 Q4	$7.47M	Buy	+185,137	New	+$5.56M	2.67%	7

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

ADAR1 Capital Management's BBIO Position: Q2 2026 in Review

ADAR1 Capital Management increased its BridgeBio Pharma (BBIO) stake by 87% in Q2 2026, buying an estimated $5.77M and bringing the position to 176,689 shares worth $13.2M. The position accounts for 0.6% of the portfolio, ranked #41.

ADAR1 Capital Management first reported a position in BBIO in Q4 2023 and has held it in 11 quarters since. The position peaked at $36.9M in Q3 2024. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

ADAR1 Capital Management held 176,689 shares of BridgeBio Pharma worth $13.2M as of Q2 2026.
ADAR1 Capital Management bought 82,397 BridgeBio Pharma shares in Q2 2026, an estimated $5.77M.
BridgeBio Pharma made up 0.6% of ADAR1 Capital Management's portfolio in Q2 2026, its #41 holding.
ADAR1 Capital Management first reported a position in BridgeBio Pharma in Q4 2023 and has held it in 11 quarters since.
ADAR1 Capital Management's BridgeBio Pharma position peaked at $36.9M in Q3 2024.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.